Cargando…
Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report
Malignancies with unknown primaries contribute to a small yet significant percentage of overall tumors. Neuroendocrine carcinomas, a rare disease with a poor prognosis, have been known to present as an unknown primary. Treatment consists of cytotoxic chemotherapy but given the latter’s high toxicity...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247284/ https://www.ncbi.nlm.nih.gov/pubmed/35783669 http://dx.doi.org/10.1177/2050313X221106987 |